12:00 AM
May 21, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Prolensa bromfenac: Additional Phase III data

Additional data from a double-blind, U.S. Phase III trial in 220 patients undergoing unilateral cataract surgery showed that 49.1% of patients receiving once-daily Prolensa achieved complete absence of ocular inflammation at day 14 post-surgery, the primary endpoint, vs. 31.8% for placebo (p=0.0132). Additionally, 76.4% of patients receiving Prolensa experienced no pain at day 1 post-surgery, a secondary endpoint, vs. 55.5% for placebo (p=0.0017). Patients began dosing with once-daily Prolensa or placebo 1 day before surgery and continued treatment for 14 days following surgery. Data...

Read the full 399 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >